First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

September 30, 2012

Conditions
Lung Cancer
Interventions
DRUG

Pemetrexed

pemetrexed 500 mg/m2

DRUG

Gemcitabine

gemcitabine 1500 mg/m2

DRUG

Bevacizumab

bevacizumab 10mg/kg bevacizumab 15mg/kg

DRUG

Carboplatin

carboplatin AUC=5

Trial Locations (18)

28801

Cancer Care of Western North Carolina, Asheville

29303

Spartanburg Regional Medical Center, Spartanburg

30060

Wellstar Cancer Research, Marietta

30501

Northeast Georgia Medical Center, Gainesville

33805

Watson Clinic Center for Cancer Care and Research, Lakeland

33901

Florida Cancer Specialists, Fort Myers

36207

Northeast Alabama Regional Medical Center, Anniston

37023

Tennessee Oncology, PLLC, Nashville

37404

Associates in Hematology Oncology, Chattanooga

Chattanooga Oncology Hematology Associates, Chattanooga

40207

Consultants in Blood Disorders and Cancer, Louisville

42101

Graves-Gilbert Clinic, Bowling Green

45242

Oncology Hematology Care, Cincinnati

47802

Providence Medical Group, Terre Haute

49503

Grand Rapids Clinical Oncology Program, Grand Rapids

68114

Methodist Cancer Center, Omaha

72401

NEA Baptist Clinic, Jonesboro

04101

Mercy Hospital, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER